Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2020-09-29 Regulatory Filings
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Full accounts made up to 2020-03-31
Regulatory Filings
2020-09-29 English
Result of AGM
AGM Information Classification · 99% confidence The document explicitly states 'Result of AGM' and mentions that 'all resolutions were duly passed' at the 'Annual General Meeting held earlier today'. This directly corresponds to the purpose of an AGM result announcement. While it is distributed via RNS (RNS Number: 1642A), the core subject matter is the outcome of the AGM, making 'AGM Information (Code: AGM-R)' the most specific and appropriate classification. It is not the full presentation (AGM-R definition implies presentations/materials), but the result announcement, which is closely related. However, since the document is very short and primarily announces the result and points to where the full details are located, it could also be considered a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific mention of 'Result of AGM' and the context of shareholder meetings, AGM-R is the best fit among the specific options, although DVA (Declaration of Voting Results) is also highly relevant. Since AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', and this is the result, I will select AGM-R as the primary classification, as it is more specific than DVA (which focuses purely on voting results) or RNS/RPA (which are general announcements).
2020-09-25 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification released via RNS (RNS Number: 0499A) concerning a transaction involving shares held by a Non-Executive Director, Alan Mawson. The content explicitly details the sale of ordinary shares by a Director/PDMR (Person Discharging Managerial Responsibilities) and provides the required regulatory breakdown under the EU Market Abuse Regulation. This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the 'Director's Dealing' category.
2020-09-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly identified as a 'TR-1: Standard form for notification of major holdings' and carries an 'RNS Number'. RNS stands for Regulatory News Service, which is the primary channel for official regulatory announcements to the London Stock Exchange. The content details changes in voting rights percentages (crossing thresholds) by a shareholder (Canaccord Genuity Group Inc.) in Fusion Antibodies PLC. This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although it is an RNS filing, MRQ is a more specific classification than the general RNS fallback.
2020-09-22 English
Update on R&D programme
Regulatory Filings Classification · 98% confidence The document is clearly identified as an RNS announcement by the presence of the 'RNS Number' header and the concluding boilerplate text referencing RNS, the London Stock Exchange, and the FCA. The content is a brief operational update regarding R&D progress on coronavirus antigens and antibody libraries, dated September 18, 2020. This type of timely, non-periodic operational or business update, especially one originating from the RNS system, fits best under the general 'Regulatory Filings' category (RNS) as it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific corporate action like a dividend or share transaction. It is a general regulatory announcement.
2020-09-18 English
Notice of AGM
AGM Information Classification · 98% confidence The document explicitly states: "Fusion Antibodies plc... announces that its Annual Report and Accounts for the year ended 31 March 2020, the Notice of Annual General Meeting ('AGM') and a Form of Proxy will be posted to shareholders later today..." and provides details about the upcoming AGM, including the date, time, and procedural changes due to COVID-19. Since the document is an announcement regarding the posting of the Annual Report AND the Notice of AGM, it covers elements of both the Annual Report (10-K) and AGM Information (AGM-R). However, the primary purpose of this specific RNS release is to inform shareholders about the publication of these documents and the logistics of the AGM. Given the structure (RNS Number, announcement title 'Posting of Annual Report and Notice of AGM'), this fits best as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the document specifically mentions the 'Notice of Annual General Meeting' and details about the AGM procedures, and the AGM materials are often released concurrently, classifying it as AGM-R (AGM Information) is highly relevant, but the 'Menu vs Meal' rule suggests that an announcement about the publication of reports/notices leans towards RPA or RNS. Because it contains the Notice of AGM and details about the closed meeting, AGM-R is a strong candidate, but RPA captures the 'announcement of posting' aspect. Given the dual nature, and the fact that the AGM details are central, I will check the definitions. AGM-R is for 'Presentations and materials shared during the AGM'. This is the *Notice* of the AGM, not the presentation. RPA is for 'Announcement regarding the timing, release, or publication of company reports'. This document is clearly an announcement of the publication of the Annual Report and the Notice of AGM. Therefore, RPA is the most precise fit for this announcement format.
2020-08-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.